Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 558 entries
Sorted by: Best Match Show Resources per page
Digestive disease week 2000. American Association for the Study of Liver Diseases.

IDrugs : the investigational drugs journal

Rosenthal P.
PMID: 16059798
IDrugs. 2000 Aug;3(8):868-71.

The latest advances in hepatology were presented in oral and poster presentations. In order to cover the varying subspecialties, the sessions were divided into various sections including 'Acute Liver Failure and Artificial Liver Support', 'Biliary Tract and Immunologic Liver...

Cite
Rosenthal P. Digestive disease week 2000. American Association for the Study of Liver Diseases. IDrugs. 2000;3(8):868-71
Rosenthal, P. (2000). Digestive disease week 2000. American Association for the Study of Liver Diseases. IDrugs : the investigational drugs journal, 3(8), 868-71.
Rosenthal, P. "Digestive disease week 2000. American Association for the Study of Liver Diseases." IDrugs : the investigational drugs journal vol. 3,8 (2000): 868-71.
Rosenthal P. Digestive disease week 2000. American Association for the Study of Liver Diseases. IDrugs. 2000 Aug;3(8):868-71. PMID: 16059798.
Copy Download .nbib Format: NLM
Therapeutic approaches to the problem of biliary sludge and gallstone formation during total parenteral nutrition.

Clinical nutrition (Edinburgh, Scotland)

Murray FE, Hawkey CJ.
PMID: 16839963
Clin Nutr. 1992 Feb;11(1):12-7. doi: 10.1016/0261-5614(92)90057-w.

Prolonged total parenteral nutrition is associated with the development of biliary sludge, which consists of super-saturated bile containing cholesterol crystals, bilirubin granules and a very high concentration of mucin glycoprotein. Reduced gallbladder contractility in TPN patients appears to be...

Cite
Murray FE, Hawkey CJ. Therapeutic approaches to the problem of biliary sludge and gallstone formation during total parenteral nutrition. Clin Nutr. 1992;11(1):12-7doi: 10.1016/0261-5614(92)90057-w.
Murray, F. E., & Hawkey, C. J. (1992). Therapeutic approaches to the problem of biliary sludge and gallstone formation during total parenteral nutrition. Clinical nutrition (Edinburgh, Scotland), 11(1), 12-7. https://doi.org/10.1016/0261-5614(92)90057-w
Murray, F E, and Hawkey, C J. "Therapeutic approaches to the problem of biliary sludge and gallstone formation during total parenteral nutrition." Clinical nutrition (Edinburgh, Scotland) vol. 11,1 (1992): 12-7. doi: https://doi.org/10.1016/0261-5614(92)90057-w
Murray FE, Hawkey CJ. Therapeutic approaches to the problem of biliary sludge and gallstone formation during total parenteral nutrition. Clin Nutr. 1992 Feb;11(1):12-7. doi: 10.1016/0261-5614(92)90057-w. PMID: 16839963.
Copy Download .nbib Format: NLM
Management of patients with primary biliary cirrhosis: a practical guide.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Nishio A, Neuberger J, Gershwin ME.
PMID: 18031174
BioDrugs. 1999 Sep;12(3):159-73. doi: 10.2165/00063030-199912030-00001.

Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease that predominantly occurs in middle-aged women. It is characterised by inflammatory destruction of interlobular and septal bile ducts, subsequent fibrosis, and finally liver cirrhosis. The disease slowly progresses over...

Cite
Nishio A, Neuberger J, Gershwin ME. Management of patients with primary biliary cirrhosis: a practical guide. BioDrugs. 1999;12(3):159-73doi: 10.2165/00063030-199912030-00001.
Nishio, A., Neuberger, J., & Gershwin, M. E. (1999). Management of patients with primary biliary cirrhosis: a practical guide. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 12(3), 159-73. https://doi.org/10.2165/00063030-199912030-00001
Nishio, A, et al. "Management of patients with primary biliary cirrhosis: a practical guide." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 12,3 (1999): 159-73. doi: https://doi.org/10.2165/00063030-199912030-00001
Nishio A, Neuberger J, Gershwin ME. Management of patients with primary biliary cirrhosis: a practical guide. BioDrugs. 1999 Sep;12(3):159-73. doi: 10.2165/00063030-199912030-00001. PMID: 18031174.
Copy Download .nbib Format: NLM
What is the influence of long-term ursodeoxycholic acid therapy in patients with primary biliary cirrhosis?.

Nature clinical practice. Gastroenterology & hepatology

Clark VC, Levy C.
PMID: 17290236
Nat Clin Pract Gastroenterol Hepatol. 2007 Apr;4(4):188-9. doi: 10.1038/ncpgasthep0741. Epub 2007 Feb 06.

No abstract available.

Cite
Clark VC, Levy C. What is the influence of long-term ursodeoxycholic acid therapy in patients with primary biliary cirrhosis?. Nat Clin Pract Gastroenterol Hepatol. 2007;4(4):188-9doi: 10.1038/ncpgasthep0741.
Clark, V. C., & Levy, C. (2007). What is the influence of long-term ursodeoxycholic acid therapy in patients with primary biliary cirrhosis?. Nature clinical practice. Gastroenterology & hepatology, 4(4), 188-9. https://doi.org/10.1038/ncpgasthep0741
Clark, Virginia C, and Levy, Cynthia. "What is the influence of long-term ursodeoxycholic acid therapy in patients with primary biliary cirrhosis?." Nature clinical practice. Gastroenterology & hepatology vol. 4,4 (2007): 188-9. doi: https://doi.org/10.1038/ncpgasthep0741
Clark VC, Levy C. What is the influence of long-term ursodeoxycholic acid therapy in patients with primary biliary cirrhosis?. Nat Clin Pract Gastroenterol Hepatol. 2007 Apr;4(4):188-9. doi: 10.1038/ncpgasthep0741. Epub 2007 Feb 06. PMID: 17290236.
Copy Download .nbib Format: NLM
Primary sclerosing cholangitis: High-dose ursodeoxycholic acid is associated with risk of colonic neoplasia in patients with PSC and ulcerative colitis.

Nature reviews. Gastroenterology & hepatology

Franks I.
PMID: 21725347
Nat Rev Gastroenterol Hepatol. 2011 Jul 04;8(7):361. doi: 10.1038/nrgastro.2011.99.

No abstract available.

Cite
Franks I. Primary sclerosing cholangitis: High-dose ursodeoxycholic acid is associated with risk of colonic neoplasia in patients with PSC and ulcerative colitis. Nat Rev Gastroenterol Hepatol. 2011;8(7):361doi: 10.1038/nrgastro.2011.99.
Franks, I. (2011). Primary sclerosing cholangitis: High-dose ursodeoxycholic acid is associated with risk of colonic neoplasia in patients with PSC and ulcerative colitis. Nature reviews. Gastroenterology & hepatology, 8(7), 361. https://doi.org/10.1038/nrgastro.2011.99
Franks, Isobel. "Primary sclerosing cholangitis: High-dose ursodeoxycholic acid is associated with risk of colonic neoplasia in patients with PSC and ulcerative colitis." Nature reviews. Gastroenterology & hepatology vol. 8,7 (2011): 361. doi: https://doi.org/10.1038/nrgastro.2011.99
Franks I. Primary sclerosing cholangitis: High-dose ursodeoxycholic acid is associated with risk of colonic neoplasia in patients with PSC and ulcerative colitis. Nat Rev Gastroenterol Hepatol. 2011 Jul 04;8(7):361. doi: 10.1038/nrgastro.2011.99. PMID: 21725347.
Copy Download .nbib Format: NLM
The Multiple Facets of ABCB4 (MDR3) Deficiency.

Current treatment options in gastroenterology

Sundaram SS, Sokol RJ.
PMID: 18221610
Curr Treat Options Gastroenterol. 2007 Dec;10(6):495-503. doi: 10.1007/s11938-007-0049-4.

ABCB4 (MDR3), a lipid translocator, moves phosphatidylcholine from the inner to the outer leaflet of the canalicular membrane. Genetic mutations of ABCB4 lead to three distinct but related hepatobiliary diseases. Progressive familial intrahepatic cholestasis (PFIC) type 3 is a...

Cite
Sundaram SS, Sokol RJ. The Multiple Facets of ABCB4 (MDR3) Deficiency. Curr Treat Options Gastroenterol. 2007;10(6):495-503doi: 10.1007/s11938-007-0049-4.
Sundaram, S. S., & Sokol, R. J. (2007). The Multiple Facets of ABCB4 (MDR3) Deficiency. Current treatment options in gastroenterology, 10(6), 495-503. https://doi.org/10.1007/s11938-007-0049-4
Sundaram, Shikha S, and Sokol, Ronald J. "The Multiple Facets of ABCB4 (MDR3) Deficiency." Current treatment options in gastroenterology vol. 10,6 (2007): 495-503. doi: https://doi.org/10.1007/s11938-007-0049-4
Sundaram SS, Sokol RJ. The Multiple Facets of ABCB4 (MDR3) Deficiency. Curr Treat Options Gastroenterol. 2007 Dec;10(6):495-503. doi: 10.1007/s11938-007-0049-4. PMID: 18221610; PMCID: PMC3888315.
Copy Download .nbib Format: NLM
Portal hypertension in primary biliary cirrhosis (PBC): A reversible condition? Yes, but not in all UDCA treated patients.

Hepatology research : the official journal of the Japan Society of Hepatology

Huet PM, Vincent C, Deslauriers J, Coté J, Fenyves D, Matsutani S, Boileau R, Kerckvoorde JH.
PMID: 19796042
Hepatol Res. 2009 Oct;39(10):1032-8. doi: 10.1111/j.1872-034X.2009.00550.x.

Portal hypertension is not a rare complication of PBC, but there are no useful clinical predictors of its severity. In fact, in PBC patients, the evaluation of portal hypertension needs a direct access to the portal vein in order...

Cite
Huet PM, Vincent C, Deslauriers J, et al. Portal hypertension in primary biliary cirrhosis (PBC): A reversible condition? Yes, but not in all UDCA treated patients. Hepatol Res. 2009;39(10):1032-8doi: 10.1111/j.1872-034X.2009.00550.x.
Huet, P. M., Vincent, C., Deslauriers, J., Coté, J., Fenyves, D., Matsutani, S., Boileau, R., & Kerckvoorde, J. H. (2009). Portal hypertension in primary biliary cirrhosis (PBC): A reversible condition? Yes, but not in all UDCA treated patients. Hepatology research : the official journal of the Japan Society of Hepatology, 39(10), 1032-8. https://doi.org/10.1111/j.1872-034X.2009.00550.x
Huet, Pierre-Michel, et al. "Portal hypertension in primary biliary cirrhosis (PBC): A reversible condition? Yes, but not in all UDCA treated patients." Hepatology research : the official journal of the Japan Society of Hepatology vol. 39,10 (2009): 1032-8. doi: https://doi.org/10.1111/j.1872-034X.2009.00550.x
Huet PM, Vincent C, Deslauriers J, Coté J, Fenyves D, Matsutani S, Boileau R, Kerckvoorde JH. Portal hypertension in primary biliary cirrhosis (PBC): A reversible condition? Yes, but not in all UDCA treated patients. Hepatol Res. 2009 Oct;39(10):1032-8. doi: 10.1111/j.1872-034X.2009.00550.x. PMID: 19796042.
Copy Download .nbib Format: NLM
Adsorption of Lithocholic Acid to Fusarium equiseti M41 as an Essential Process in Its Conversion to Ursodeoxycholic Acid.

Applied and environmental microbiology

Nihira T, Nishino T, Maehara M, Kulprecha S, Yoshida T, Taguchi H.
PMID: 16347578
Appl Environ Microbiol. 1988 Mar;54(3):670-675. doi: 10.1128/aem.54.3.670-675.1988.

Fusarium equiseti M41 converts lithocholic acid to ursodeoxycholic acid. Adsorption of lithocholic acid particles to mycelia of F. equiseti M41 is essential in the conversion of lithocholic acid to ursodeoxycholic acid. Production of ursodeoxycholic acid was negligible when particles...

Cite
Nihira T, Nishino T, Maehara M, et al. Adsorption of Lithocholic Acid to Fusarium equiseti M41 as an Essential Process in Its Conversion to Ursodeoxycholic Acid. Appl Environ Microbiol. 1988;54(3):670-675doi: 10.1128/aem.54.3.670-675.1988.
Nihira, T., Nishino, T., Maehara, M., Kulprecha, S., Yoshida, T., & Taguchi, H. (1988). Adsorption of Lithocholic Acid to Fusarium equiseti M41 as an Essential Process in Its Conversion to Ursodeoxycholic Acid. Applied and environmental microbiology, 54(3), 670-675. https://doi.org/10.1128/aem.54.3.670-675.1988
Nihira, Takuya, et al. "Adsorption of Lithocholic Acid to Fusarium equiseti M41 as an Essential Process in Its Conversion to Ursodeoxycholic Acid." Applied and environmental microbiology vol. 54,3 (1988): 670-675. doi: https://doi.org/10.1128/aem.54.3.670-675.1988
Nihira T, Nishino T, Maehara M, Kulprecha S, Yoshida T, Taguchi H. Adsorption of Lithocholic Acid to Fusarium equiseti M41 as an Essential Process in Its Conversion to Ursodeoxycholic Acid. Appl Environ Microbiol. 1988 Mar;54(3):670-675. doi: 10.1128/aem.54.3.670-675.1988. PMID: 16347578; PMCID: PMC202523.
Copy Download .nbib Format: NLM
Antimitochondrial antibodies and their significance in diffuse and limited scleroderma.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Pope JE, Thompson A.
PMID: 19078387
J Clin Rheumatol. 1999 Aug;5(4):206-9. doi: 10.1097/00124743-199908000-00005.

The increased prevalence of primary biliary cirrhosis (PBC) in Sjogren's syndrome and scleroderma has been described. We determined the frequency of antimitochondrial antibodies (AMA) in limited scleroderma, compared with diffuse scleroderma, and have considered their clinical significance because they...

Cite
Pope JE, Thompson A. Antimitochondrial antibodies and their significance in diffuse and limited scleroderma. J Clin Rheumatol. 1999;5(4):206-9doi: 10.1097/00124743-199908000-00005.
Pope, J. E., & Thompson, A. (1999). Antimitochondrial antibodies and their significance in diffuse and limited scleroderma. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 5(4), 206-9. https://doi.org/10.1097/00124743-199908000-00005
Pope, J E, and Thompson, A. "Antimitochondrial antibodies and their significance in diffuse and limited scleroderma." Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases vol. 5,4 (1999): 206-9. doi: https://doi.org/10.1097/00124743-199908000-00005
Pope JE, Thompson A. Antimitochondrial antibodies and their significance in diffuse and limited scleroderma. J Clin Rheumatol. 1999 Aug;5(4):206-9. doi: 10.1097/00124743-199908000-00005. PMID: 19078387.
Copy Download .nbib Format: NLM
Natural history of primary biliary cirrhosis.

Hepatology research : the official journal of the Japan Society of Hepatology

Abe M, Onji M.
PMID: 18462379
Hepatol Res. 2008 Jul;38(7):639-45. doi: 10.1111/j.1872-034X.2008.00351.x. Epub 2008 May 06.

The natural history of primary biliary cirrhosis (PBC) has improved significantly over the last two decades. Most patients are diagnosed with asymptomatic PBC (a-PBC). The prognosis of a-PBC is usually better than that of symptomatic PBC (s-PBC). Among a-PBC...

Cite
Abe M, Onji M. Natural history of primary biliary cirrhosis. Hepatol Res. 2008;38(7):639-45doi: 10.1111/j.1872-034X.2008.00351.x.
Abe, M., & Onji, M. (2008). Natural history of primary biliary cirrhosis. Hepatology research : the official journal of the Japan Society of Hepatology, 38(7), 639-45. https://doi.org/10.1111/j.1872-034X.2008.00351.x
Abe, Masanori, and Onji, Morikazu. "Natural history of primary biliary cirrhosis." Hepatology research : the official journal of the Japan Society of Hepatology vol. 38,7 (2008): 639-45. doi: https://doi.org/10.1111/j.1872-034X.2008.00351.x
Abe M, Onji M. Natural history of primary biliary cirrhosis. Hepatol Res. 2008 Jul;38(7):639-45. doi: 10.1111/j.1872-034X.2008.00351.x. Epub 2008 May 06. PMID: 18462379.
Copy Download .nbib Format: NLM
The effect of ursodeoxycholic acid on liver regeneration after partial hepatectomy in rats with non-alcoholic fatty liver disease.

Hepatology research : the official journal of the Japan Society of Hepatology

Uzun MA, Koksal N, Aktas S, Gunerhan Y, Kadioglu H, Dursun N, Sehirli AO.
PMID: 19473430
Hepatol Res. 2009 Aug;39(8):814-21. doi: 10.1111/j.1872-034X.2009.00511.x. Epub 2009 Apr 03.

AIM: To investigate the effect of ursodeoxycholic acid (UDCA) on liver regeneration following partial hepatectomy in rats with non-alcoholic fatty liver disease (NAFLD).METHODS: UDCA was administered to seven rats (group 1) and physiological saline was administered both to seven...

Cite
Uzun MA, Koksal N, Aktas S, et al. The effect of ursodeoxycholic acid on liver regeneration after partial hepatectomy in rats with non-alcoholic fatty liver disease. Hepatol Res. 2009;39(8):814-21doi: 10.1111/j.1872-034X.2009.00511.x.
Uzun, M. A., Koksal, N., Aktas, S., Gunerhan, Y., Kadioglu, H., Dursun, N., & Sehirli, A. O. (2009). The effect of ursodeoxycholic acid on liver regeneration after partial hepatectomy in rats with non-alcoholic fatty liver disease. Hepatology research : the official journal of the Japan Society of Hepatology, 39(8), 814-21. https://doi.org/10.1111/j.1872-034X.2009.00511.x
Uzun, Mehmet Ali, et al. "The effect of ursodeoxycholic acid on liver regeneration after partial hepatectomy in rats with non-alcoholic fatty liver disease." Hepatology research : the official journal of the Japan Society of Hepatology vol. 39,8 (2009): 814-21. doi: https://doi.org/10.1111/j.1872-034X.2009.00511.x
Uzun MA, Koksal N, Aktas S, Gunerhan Y, Kadioglu H, Dursun N, Sehirli AO. The effect of ursodeoxycholic acid on liver regeneration after partial hepatectomy in rats with non-alcoholic fatty liver disease. Hepatol Res. 2009 Aug;39(8):814-21. doi: 10.1111/j.1872-034X.2009.00511.x. Epub 2009 Apr 03. PMID: 19473430.
Copy Download .nbib Format: NLM
Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan.

Hepatology research : the official journal of the Japan Society of Hepatology

Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Chayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y.
PMID: 20156296
Hepatol Res. 2010 Jan;40(1):8-13. doi: 10.1111/j.1872-034X.2009.00634.x.

In the 2008 guidelines for the treatment of patients with chronic hepatitis C, pegylated interferon (Peg-IFN) combined with ribavirin for 48 weeks are indicated for treatment-naive patients infected with hepatitis C virus (HCV) of genotype 1. Treatment is continued...

Cite
Kumada H, Okanoue T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010;40(1):8-13doi: 10.1111/j.1872-034X.2009.00634.x.
Kumada, H., Okanoue, T., Onji, M., Moriwaki, H., Izumi, N., Tanaka, E., Chayama, K., Sakisaka, S., Takehara, T., Oketani, M., Suzuki, F., Toyota, J., Nomura, H., Yoshioka, K., Seike, M., Yotsuyanagi, H., Ueno, Y. (2010). Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatology research : the official journal of the Japan Society of Hepatology, 40(1), 8-13. https://doi.org/10.1111/j.1872-034X.2009.00634.x
Kumada, Hiromitsu, et al. "Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan." Hepatology research : the official journal of the Japan Society of Hepatology vol. 40,1 (2010): 8-13. doi: https://doi.org/10.1111/j.1872-034X.2009.00634.x
Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Chayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010 Jan;40(1):8-13. doi: 10.1111/j.1872-034X.2009.00634.x. PMID: 20156296.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 558 entries